Table 3.
Univariate survival analysis for all patients and subgroups
| All patients (n = 4893) | Major liver resection (n = 733) | Lymph nodes evaluated (n = 658) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Agea | 1.2 | 1.1–1.2 | <0.001 | 1.1 | 1.0–1.2 | 0.022 | 1.1 | 1.0–1.2 | 0.001 |
| Male sex | 1.1 | 1.0–1.2 | 0.002 | 1.1 | 0.9–1.3 | 0.550 | 1.1 | 1.0–1.3 | 0.176 |
| Diagnosis yearb | 1.0 | 1.0–1.0 | <0.001 | 1.0 | 0.9–1.0 | <0.001 | 1.0 | 0.9–1.0 | <0.001 |
| Non-White race | 1.1 | 1.0–1.1 | 0.253 | 1.0 | 0.8–1.2 | 0.818 | 1.2 | 1.0–1.5 | 0.084 |
| Grade | |||||||||
| Well differentiated | 1.0 | – | Ref | 1.0 | – | Ref | 1.0 | – | Ref |
| Moderately differentiated | 1.1 | 1.0–1.3 | 0.100 | 1.3 | 1.0–1.9 | 0.087 | 1.3 | 1.0–1.9 | 0.101 |
| Poorly differentiated | 1.6 | 1.4–1.8 | <0.001 | 1.9 | 1.3–2.6 | <0.001 | 2.0 | 1.4–2.8 | <0.001 |
| Undifferentiated | 2.1 | 1.5–2.8 | <0.001 | 2.4 | 1.1–5.1 | 0.023 | 2.4 | 1.0–5.2 | 0.037 |
| Regional lymph node status | |||||||||
| Negative | 1.0 | – | Ref | 1.0 | – | Ref | 1.0 | – | Ref |
| Positive | 1.8 | 1.5–2.1 | <0.001 | 1.8 | 1.4–2.4 | <0.001 | 1.9 | 1.6–2.3 | <0.001 |
| Unknown | 2.3 | 2.1–2.7 | <0.001 | 1.1 | 0.9–1.3 | 0.433 | – | – | – |
| Radiation therapy | 0.7 | 0.7–0.8 | <0.001 | 1.1 | 0.9–1.4 | 0.253 | 0.9 | 0.7–1.0 | 0.115 |
| Major liver resection | 0.3 | 0.3–0.4 | <0.001 | – | – | – | 0.4 | 0.3–0.5 | <0.001 |
| Tumour size (cm) | 1.0 | 1.0–1.0 | 0.004 | 1.0 | 1.0–1.1 | 0.018 | 1.0 | 1.0–1.1 | 0.015 |
| AJCC 7th edition stage | |||||||||
| Stage I | 1.0 | – | Ref | 1.0 | – | Ref | 1.0 | – | Ref |
| Stage II | 0.9 | 0.7–1.1 | 0.169 | 1.7 | 1.2–2.5 | 0.005 | 1.4 | 0.8–2.4 | 0.296 |
| Stage III | 1.6 | 1.4–1.7 | <0.001 | 1.9 | 1.4–2.5 | <0.001 | 1.5 | 1.0–2.3 | 0.046 |
| Stage IVa | 1.3 | 1.2–1.5 | <0.001 | 2.7 | 2.1–3.4 | <0.001 | 2.5 | 1.9–3.3 | <0.001 |
| Stage IVb | 2.4 | 2.2–2.7 | <0.001 | 4.3 | 3.0–6.1 | <0.001 | 5.5 | 4.0–7.6 | <0.001 |
| AJCC 7th edition T-stagec | |||||||||
| T1 | 1.0 | – | Ref | 1.0 | – | Ref | 1.0 | – | Ref |
| T2a | 0.9 | 0.7–1.0 | 0.091 | 1.7 | 1.2–2.3 | 0.004 | 1.3 | 0.9–2.1 | 0.167 |
| T2b | 1.5 | 1.4–1.7 | <0.001 | 2.0 | 1.5–2.7 | <0.001 | 1.8 | 1.4–2.5 | <0.001 |
| T3 | 1.4 | 1.3–1.5 | <0.001 | 2.6 | 2.1–3.3 | <0.001 | 2.2 | 1.7–2.8 | <0.001 |
| AJCC 7th edition N-stage | |||||||||
| N0 | 1.0 | – | Ref | 1.0 | – | Ref | 1.0 | – | Ref |
| N1 | 1.3 | 1.2–1.4 | <0.001 | 2.0 | 1.6–2.5 | <0.001 | 1.9 | 1.6–2.3 | <0.001 |
| Unknown N-stage | 1.7 | 1.6–1.8 | <0.001 | 1.6 | 1.3–2.0 | <0.001 | – | – | – |
| AJCC 7th edition M-stage | |||||||||
| M0 | 1.0 | – | Ref | 1.0 | – | Ref | 1.0 | – | Ref |
| M1 | 2.0 | 1.8–2.1 | <0.001 | 2.5 | 1.9–3.3 | <0.001 | 2.6 | 2.2–3.2 | <0.001 |
a
Age in 10-year increments.
b
Modelled as a continuous variable.
c
The AJCC Staging Manual, 7th edition, defines T4 as tumour with periductal invasion. Cases in the SEER registry do not document periductal invasion and therefore no T4 cases were recorded.
95% CI, 95% confidence interval; HR, hazard ratio; AJCC, American Joint Committee on Cancer.